The global crisis caused by the SARS-Cov2 outbreak requires rapidly applicable therapeutics. Available approved drug substances represent one of the more realistic paths to clinical use within weeks or months.
Delta4 is aiming to use its digital drug development platform to screen repurposing opportunities for COVID-19.
Currently our computational biology staff is preparing to curate pathomechanistic models for diseases caused by corona viruses. Due to the rapid and extremly efficient Delta4 repurposing workflow, we are confident that we are able screen compounds and propose candidate therapies within a short time.